{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:27:16Z","timestamp":1760660836529,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.drugpo.2019.06.020","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T23:42:35Z","timestamp":1565394155000},"page":"96-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Potential public health impacts of medical cannabis availability on opioid-related harms? Urgent but un-answered questions from Canada"],"prefix":"10.1016","volume":"73","author":[{"given":"Benedikt","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kurdyak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2019.06.020_bib0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejim.2018.01.001","article-title":"Medical use of cannabis and cannabinoids containing products\u2013regulations in Europe and North America","volume":"49","author":"Abuhasira","year":"2018","journal-title":"European Journal of Internal Medicine"},{"issue":"10","key":"10.1016\/j.drugpo.2019.06.020_bib0010","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jamainternmed.2014.4005","article-title":"Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999\u20132010","volume":"174","author":"Bachhuber","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"4","key":"10.1016\/j.drugpo.2019.06.020_bib0015","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.drugpo.2014.02.009","article-title":"Barriers to access for Canadians who use cannabis for therapeutic purposes","volume":"25","author":"Belle-Isle","year":"2014","journal-title":"International Journal of Drug Policy"},{"issue":"6","key":"10.1016\/j.drugpo.2019.06.020_bib0020","doi-asserted-by":"crossref","first-page":"224","DOI":"10.24095\/hpcdp.38.6.02","article-title":"Evidence synthesis\u2014The opioid crisis in Canada: A national perspective","volume":"38","author":"Belzak","year":"2018","journal-title":"Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice"},{"issue":"7","key":"10.1016\/j.drugpo.2019.06.020_bib0025","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1377\/hlthaff.2015.1661","article-title":"Medical marijuana laws reduce prescription medication use in medicare part D","volume":"35","author":"Bradford","year":"2016","journal-title":"Health Affairs"},{"issue":"5","key":"10.1016\/j.drugpo.2019.06.020_bib0030","first-page":"667","article-title":"Association between US state medical cannabis laws and opioid prescribing in the medicare part D population","volume":"178","author":"Bradford","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.drugpo.2019.06.020_bib0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/09540261.2018.1509842","article-title":"What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review","volume":"30","author":"Campbell","year":"2018","journal-title":"International Review of Psychiatry"},{"year":"2017","series-title":"Opioid-related harms in Canada","author":"Canadian Institutes for Health Information","key":"10.1016\/j.drugpo.2019.06.020_bib0040"},{"key":"10.1016\/j.drugpo.2019.06.020_bib0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","article-title":"Fentanyl in the US heroin supply: A rapidly changing risk environment","volume":"46","author":"Ciccarone","year":"2017","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2019.06.020_bib0050","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2147\/JPR.S134330","article-title":"Cannabis as a substitute for prescription drugs\u2013a cross-sectional study","volume":"10","author":"Corroon","year":"2017","journal-title":"Journal of Pain Research"},{"year":"2018","series-title":"Preventing overdose deaths in Europe","author":"European Monitoring Centre for Drugs and Drug Addiction","key":"10.1016\/j.drugpo.2019.06.020_bib0055"},{"key":"10.1016\/j.drugpo.2019.06.020_bib0060","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.drugpo.2017.06.005","article-title":"Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic","volume":"46","author":"Fairbairn","year":"2017","journal-title":"International Journal of Drug Policy"},{"issue":"4","key":"10.1016\/j.drugpo.2019.06.020_bib0065","first-page":"655","article-title":"What ecologic analyses cannot tell us about medical marijuana legalization and opioid pain medication mortality","volume":"175","author":"Finney","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.drugpo.2019.06.020_bib0070","doi-asserted-by":"crossref","first-page":"146","DOI":"10.17269\/cjph.105.4143","article-title":"Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: An update 5 years later","volume":"105","author":"Fischer","year":"2014","journal-title":"Canadian Journal of Public Health"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.020_bib0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drugpo.2014.09.007","article-title":"Medical marijuana programs: Implications for cannabis control policy\u2013observations from Canada","volume":"26","author":"Fischer","year":"2015","journal-title":"International Journal of Drug Policy"},{"issue":"2","key":"10.1016\/j.drugpo.2019.06.020_bib0080","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S2468-2667(18)30232-9","article-title":"The opioid death crisis in Canada: Crucial lessons for public health","volume":"4","author":"Fischer","year":"2018","journal-title":"The Lancet Public Health"},{"key":"10.1016\/j.drugpo.2019.06.020_bib0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugpo.2016.06.014","article-title":"Realistically furthering the goals of public health by cannabis legalization with strict regulation: Response to Kalant","volume":"34","author":"Fischer","year":"2016","journal-title":"International Journal of Drug Policy"},{"issue":"17\u201318","key":"10.1016\/j.drugpo.2019.06.020_bib0090","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1503\/cmaj.160356","article-title":"Effective Canadian policy to reduce harms from prescription opioids: Learning from past failures","volume":"188","author":"Fischer","year":"2016","journal-title":"CMAJ"},{"year":"2017","series-title":"Latest trends in opioid-related deaths in Ontario: 1991 to 2015","author":"Gomes","key":"10.1016\/j.drugpo.2019.06.020_bib0095"},{"key":"10.1016\/j.drugpo.2019.06.020_bib0100","doi-asserted-by":"crossref","first-page":"k3207","DOI":"10.1136\/bmj.k3207","article-title":"Contributions of prescribed and non-prescribed opioids to opioid related deaths: Population based cohort study in Ontario, Canada","volume":"362","author":"Gomes","year":"2018","journal-title":"BMJ"},{"year":"2019","series-title":"Data on cannabis for medicinal purposes","author":"Government of Canada","key":"10.1016\/j.drugpo.2019.06.020_bib0105"},{"year":"2019","series-title":"National Report","author":"Government of Canada","key":"10.1016\/j.drugpo.2019.06.020_bib0110"},{"year":"2018","series-title":"CAMH monitor e-report: substance use, mental health and well-being among Ontario adults, 1977\u20132017","author":"Ialomiteanu","key":"10.1016\/j.drugpo.2019.06.020_bib0115"},{"issue":"11","key":"10.1016\/j.drugpo.2019.06.020_bib0120","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2105\/AJPH.2016.303426","article-title":"State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers","volume":"106","author":"Kim","year":"2016","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.drugpo.2019.06.020_bib0125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","article-title":"The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction","volume":"36","author":"Kolodny","year":"2015","journal-title":"Annual Review of Public Health"},{"issue":"6","key":"10.1016\/j.drugpo.2019.06.020_bib0130","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/dar.12275","article-title":"A safer alternative: Cannabis substitution as harm reduction","volume":"34","author":"Lau","year":"2015","journal-title":"Drug and Alcohol Review"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.020_bib0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12954-017-0183-9","article-title":"Rationale for cannabis-based interventions in the opioid overdose crisis","volume":"14","author":"Lucas","year":"2017","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.drugpo.2019.06.020_bib0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drugpo.2017.01.011","article-title":"Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients","volume":"42","author":"Lucas","year":"2017","journal-title":"International Journal of Drug Policy"},{"issue":"10","key":"10.1016\/j.drugpo.2019.06.020_bib0145","doi-asserted-by":"crossref","first-page":"371","DOI":"10.5694\/mja16.00234","article-title":"Medicinal cannabis in Australia: The missing links","volume":"204","author":"Martin","year":"2016","journal-title":"Medical Journal of Australia"},{"key":"10.1016\/j.drugpo.2019.06.020_bib0150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jhealeco.2017.12.007","article-title":"Do medical marijuana laws reduce addictions and deaths related to pain killers?","volume":"58","author":"Powell","year":"2018","journal-title":"Journal of Health Economics"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.020_bib0155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/can.2017.0012","article-title":"Cannabis as a substitute for opioid-based pain medication: Patient self-report","volume":"2","author":"Reiman","year":"2017","journal-title":"Cannabis and Cannabinoid Research"},{"key":"10.1016\/j.drugpo.2019.06.020_bib0160","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.drugalcdep.2017.07.018","article-title":"Trends in heroin and pharmaceutical opioid overdose deaths in Australia","volume":"179","author":"Roxburgh","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"5152","key":"10.1016\/j.drugpo.2019.06.020_bib0165","first-page":"1419","article-title":"Drug and opioid-involved overdose deaths \u2013 United States, 2013\u20132017","volume":"67","author":"Scholl","year":"2019","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.drugpo.2019.06.020_bib0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drugalcdep.2017.01.006","article-title":"Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever","volume":"173","author":"Shi","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.drugpo.2019.06.020_bib0175","first-page":"673","article-title":"Association of medical and adult-use marijuana laws with opioid prescribing for medicaid enrollees","volume":"178","author":"Wen","year":"2018","journal-title":"JAMA"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919301756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919301756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:44:52Z","timestamp":1760629492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395919301756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":35,"alternative-id":["S0955395919301756"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.06.020","relation":{},"ISSN":["0955-3959"],"issn-type":[{"type":"print","value":"0955-3959"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential public health impacts of medical cannabis availability on opioid-related harms? Urgent but un-answered questions from Canada","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}